Home > Journals > Public health > Cahiers d'études et de recherches francophones / Santé > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
Public health
Cahiers d'études et de recherches francophones / Santé
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Measuring drug affordability (Senegal)


Cahiers d'études et de recherches francophones / Santé . Volume 15, Number 1, 53-62, Janvier-Février-Mars 2005, Étude originale

Résumé   Article gratuit  

Author(s) : Jean Marc Guimier, Danielle Candau, Michel Garenne, Louis Teulières

Summary : This article presents the results of a global survey on drug accessibility conducted in Senegal in 2001. The original tool we developed to measure drug affordability for this study considered 5 marker diseases and their corresponding medical treatments and determined the theoretical amount that each population quintile can devote to the purchase of these treatments at market prices without damaging their economic status (affordability threshold). These results were then compared with those obtained as part of a field survey of 987 patients at 41 health centres and 51 private chemists (pharmacists). The main results show that the population’s ability to afford treatment is low (less than 40% at public sector prices and a little over 20% at private sector prices) and that even at the lowest market prices (public sector) 20% to 60% of the population cannot afford treatments for the most common illnesses. The field survey shows, moreover, that these results are exacerbated by four external factors: additional illness-associated expenditures (i.e., transportation costs, doctor visits), lack of compliance with government-set drug prices, prescription habits and dispensing practices. When these added costs are taken into account, less than 20% of the population can actually pay the public-sector treatment costs for the marker diseases, let alone the private sector prices. This tool is also useful for highlighting the insufficiencies of the strategies adopted for the target diseases (inconsistency between pricing policies and health priorities) and for providing a baseline measurement (at t 0) of different socioeconomic groups’ access to given treatments. Improvement or deterioration can then be assessed with measurements at times t 1, t 2…t n.

Keywords : drug, cost, access to drug, health policy, Senegal

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]